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Abstract Renal cell carcinoma (RCC) displays strong
resistance against many chemotherapeutic drugs. Over-
expression of P-glycoprotein (Pgp) appears to be part of
this resistance. The involvement of another resistance
mechanism, involving the decreased activity of DNA
topoisomerase II (topoII), remains uncertain. By cul-
turing the human RCC lines RC2 and RC21 in the
presence of increasing concentrations of etoposide, we
derived the variant sublines RC2E, RC21A and RC21E,
that had acquired approximately 30-, 60- and 90-fold
resistance to this drug respectively. RC2E, RC21A and
RC21E were approximately 50-, 5- and 400-fold cross-
resistant to doxorubicin respectively. RC2E and RC21E
also showed cross-resistance (approximately 200- and
3500-fold respectively) to vinblastine. Quantitative dif-
ferences in MDR1 and Pgp expression (elevated in
RC2E and RC21E) and topoIIa (reduced in RC21E and
RC21A) were demonstrated using Western blotting and
the reverse transcriptase/polymerase chain reaction.
Decreased amounts of topoIIa were reflected in a re-
duced activity of RC21A and RC21E as measured by
unknotting phage P4 DNA. Qualitative changes of the
topoIIa gene, such as point mutations in the motif B/
DNBS and DNA-binding regions, or dierences in
methylation status of the promoter gene of RC21E, were
not found. These cell lines represent a model of a solid
tumor in which overexpression of Pgp, a combination of
increased Pgp and decreased topoIIa, and a decrease of
topoIIa are represented.
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Introduction
Nearly 30% of patients with renal cell carcinoma (RCC)
present with metastases at the time of diagnosis. As
surgical treatment will be eective only for localized
disease, curative therapy is not possible for these pa-
tients. Presently available chemotherapeutic drugs, ad-
ministered according to standard scheduling, fail to
achieve response rates of more than 7%, which might
even partly represent an indirect cytotoxic eect (Ya-
goda et al. 1995). The relative insensitivity of tumor cells
to a broad range of cytotoxic agents is called multidrug
resistance (MDR). Insights into the mechanisms re-
sponsible for MDR should contribute to the develop-
ment of more eective chemotherapeutic treatments for
RCC. One of the best known resistance mechanisms
implicated in MDR of RCC consists of overexpression
of theMDR1 gene and its product P-glycoprotein (Pgp),
an energy-dependent multidrug transmembrane trans-
porter that prevents intracellular accumulation of cyto-
toxic drugs by rapidly extruding them (Kakehi et al.
1988). This form of drug resistance (Pgp-MDR) can be
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circumvented in vitro by chemosensitisers that interact
with and block the drug-eux function of Pgp (Kakehi
et al. 1988). Clinical investigations using these reverting
agents in combination with cytotoxic drugs have been
initiated (Mickisch et al. 1990), but the results of these
eorts have not been very rewarding so far (Mickisch
et al. 1996; Motzer et al. 1995), despite progress in the
availability of modern chemosensitisers. These poor re-
sults may suggest that other mechanisms of MDR may
be operational in RCC. Because RCC specimens display
varying levels of Pgp expression (Kanamaru et al. 1989;
Volm et al. 1993), Pgp-MDR may be only one of the
contributing factors to the MDR of RCC. Other
mechanisms of MDR have now been identified. One of
these, termed altered-topoisomerase MDR or at-MDR
(Beck et al. 1994a; Hochhauser and Harris 1993), is as-
sociated with decreased activity of the nuclear enzyme
topoisomerase II (topoII). This enzyme can alter the
topological state of DNA during cell-cycle activities
(Wang 1987). The action of topoII includes cleavage of
double-stranded DNA, ATP-dependent passage of a
secondary DNA strand through this cleavage site and
rejoining of broken DNA (Oshero et al. 1994). This
happens at sites that are exposed to torsional stress of
the highly compacted DNA incurred during DNA rep-
lication, RNA transcription, and segregation of chro-
mosomes during mitosis. During the breaking and
rejoining of double-stranded DNA, topoII and DNA
form covalently bound complexes, termed cleavable
complexes. The mechanism of action of certain topoII
inhibitors, such as the epipodophylotoxins, is to stabilize
these cleavable complexes (Liu et al. 1983), thus pre-
venting strand religation and further DNA processing,
which eventually will lead to cell death (Beck et al.
1994b; Kamesaki et al. 1993; Pommier 1993). The two
mammalian isoforms of topoII, topoIIa (170 kDa) and
topoIIb (180 kDa) (Drake et al. 1987; Tan et al. 1992),
have very similar regions, suggesting a comparable mode
of action (Chung et al. 1989), but they dier in cell-cycle
distribution. Expression of topoIIa varies during cell
cycle, whereas topoIIb appears to be constant (Kimura
et al. 1994; Woessner et al. 1990). Altered topoIIa ac-
tivity, which can be caused by quantitative (Fry et al.
1991; Gudkov et al. 1993; Kim and Beck 1994; Ritke
and Yalowich 1993) or qualitative (Danks et al. 1993;
Hinds et al. 1991) changes, can result in reduced num-
bers of drug-stabilized cleavable complexes and is likely
to influence cellular sensitivity to topoII inhibitors.
We investigated whether at-MDR plays a role in the
chemoresistance of RCC, as previously suggested (Volm
et al. 1993). Our aim was to develop a preclinical model
for chemotherapeutic drug studies of RCC by estab-
lishing a panel of cloned cell lines expressing the at-
MDR and/or Pgp-MDR phenotypes via pulsed
treatment of previously unselected RCC cell lines with
VP-16. The resistance of these newly established RCC
sublines against topoII-inhibiting and non-topoisomer-
ase-inhibiting drugs was assessed in relation to altera-
tions in resistance-related gene expression, protein
expression and protein activity. In addition, factors that
may be responsible for the observed alterations were
studied, such as gene mutations in certain regions of
interest and methylation within the promoter region of
the topoIIa gene.
Materials and methods
Cell culture and conditions
Two non-chemoselected human RCC cell lines, RC2 and RC21,
originally established in our laboratory (Grossi et al. 1992) and
three resistant sublines were examined. All RCC cell lines were
cultured in DMEM-F12 medium supplemented with 7.5% fetal calf
serum, 1 E/ml penicillin, 1lg/ml streptomycin and 2 mM gluta-
mine (Gibco BRL Europe, Breda, The Netherlands) at 37°C in a
humidified atmosphere supplemented with 5% CO2. Resistant cell
lines were derived from the parental cell lines by selection in in-
creasing concentrations (0.033–10 lg/ml) of etoposide (Bristol-
Meyers, Syracuse, USA). Nearly confluent cultures were exposed
for 48 h to etoposide in concentrations that killed approximately
90% of the cells. After this treatment cultures were allowed to
repopulate and then reexposed to a higher drug concentration for
another 48 h. Thus, the etoposide dose was increased stepwise until
cultures continued to grow exponentially in the presence of up to
10 lg/ml. The RC21A subline was obtained after 5 months,
whereas the RC2E and RC21E lines were both isolated after ap-
proximately 8 months. Finally, the sublines were cloned by the
limiting-dilution technique and characterized with respect to their
resistance to etoposide and to vinblastine (E. Lilly Nederland,
Nieuwegein, The Netherlands). The human leukemic CCRF-CEM
cell line and its subline CEM/VM-1-5, resistant to teniposide
(Danks et al. 1988), served as controls for some of the assays. All
cell cultures used for experiments were in logarithmic growth and
had been found to be negative for Mycoplasma.
Growth inhibition assays
Chemosensitivities of parental cell lines and derived sublines were
determined using the microtiter tetrazolium test (Romijn et al.
1988). Exponentially growing cells were detached with trypsin/
EDTA (Gibco) and equal numbers of cells were plated with 100 ll
medium in 96-well plates (Costar, Cambridge, Mass.). We used
separate plates for each cell line and each drug. Plating densities
were chosen such that exponential growth was maintained
throughout the subsequent 4-day culture period. Drugs were added
24 h after plating in ten dierent concentrations, dissolved in
100 ll culture medium. Cytotoxic drugs used were etoposide, vin-
blastine, and doxorubicin (Pharmachemie, The Netherlands). After
incubation with cytotoxic drugs for 72 h, 30 ll 5-mg/ml solution of
dimethylthiazoldiphenyltetrazolium bromide (Sigma, St Louis,
Mo.) in phosphate-buered saline was added. After 4 h the fluid
content of each well was aspirated carefully and the purple form-
azan precipitate dissolved upon shaking for 3 min in 100 ll 90%
dimethylsulfoxide buered with 0.01 M glycine and 0.01 M NaCl
(pH 10.5). Absorbances were measured at 570 nm using a BioRad
microplate reader model 450 (BioRad, Hercules, Calif.). The re-
duction in absorbance at each drug concentration (8 wells) was
expressed relative to the untreated controls. IC50 values were de-
termined from dose/inhibition curves. Resistance of sublines rela-
tive to parental lines was expressed as the ratio of their IC50 values
(the median inhibitory dose).
Topoisomerase unknotting activity
Isolated nuclei were used to obtain nuclear protein extracts as de-
scribed before (Danks et al. 1988). Exponentially growing cells
(approximately 108) were permeabilized by incubation in hypotonic
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buer I (5 mM KH2PO4, 2 mM MgCl2, 4 mM dithiothreitol
(DTT), 0.1 mM Na2EDTA, pH 7.0). When almost all cells were
stained with trypan blue, they were pelleted at 400 g for 5 min and
suspended in 2 ml buer II (buer I with 0.25 M sucrose). This
suspension was layered over 3 ml buer III (buer I with 0.6 M
sucrose) and centrifuged at 2000 g for 20 min. The pellet of isolated
nuclei was then incubated in a half-volume of buer IV (5 mM
KH2PO4, 4 mM DTT, 1 mM Na2EDTA, pH 7.0) on ice for
15 min. For 1.0 M salt extracts of nuclear protein, another half-
volume of buer V (40 mM TRIS, 2 M NaCl, 4 mM DTT, 20%
glycerol, pH 7.5) was added. After incubation on ice for 30 min, the
suspension was centrifuged at 100 000 g for 60 min, protein con-
centration was determined, and aliquots of this solution were
stored at ÿ80C. In all buers proteinase inhibitors were included.
P4 DNA (knotted phage DNA) was used as a substrate to
measure the unknotting activity of topoII in the nuclear extracts, as
described previously (Danks et al. 1988). Activity profiles were
assessed by electrophoresis of the products in 0.7% agarose, sub-
sequent staining of the gels with ethidium bromide and photo-
graphing under UV illumination.
Gene expression and mutation analysis
Total cellular RNA was extracted with the Stat-60 RNA isolation
kit (Biotecx Laboratories Inc., Houston, Tex.), according to the
manufacturer’s directions, and used for single-strand conforma-
tional polymorphism (SSCP) analysis of point mutations (Danks
et al. 1993) and quantifitation by the reverse transcriptase/poly-
merase chain reaction (RT-PCR). RNA quantity and quality were
checked spectrophotometrically. To generate cDNA from RNA
templates, each sample tube included 0.5 lg total RNA; 5 mM
MgCl2; 1 mM each dGTP, dATP, dTTP, dCTP; 0.5 unit RNase
inhibitor; 2.5 lM random primers; and 1.25 units reverse trans-
criptase, in a volume of 10 ll. All reagents used for PCR were from
Promega (Madison, Wis.). The RT program used was 15 min at
42°C, 5 min at 99°C and 5 min at 5°C. To amplify specific regions
from the cDNA, 40 ll was added of the following solution: 2 mM
MgCl2, 0.5 lM each primer, 1.25 units Taq polymerase and, if used
for SSCP analysis, 1 lCi [32P]dATP. The program to amplify
double-stranded DNA was 28 cycles of 30 s at 94°C, 30 s at 55°C,
and 90 s at 72°C. Primer sets used for SSCP were for the ATP-
binding sites motif B/DNBS (Danks et al. 1993) of topoIIa: 5¢-
ATA ATA GAA TCA AGG GAA TTC CCA AAC TCG A-3¢
(sense) and 5¢-CTT GTA CTG CAG ACC CAC A-3¢ (antisense),
and for the DNA-binding region adjacent to Tyr-805 of topoIIa: 5¢-
CAA TTA GCT GGA TCC GTG GCT GAA ATG TC-3¢ (sense)
and 5¢-CAG TAC CGA TTC CTG CAG CAC CAT TTA TC-3¢
(antisense). RT-PCR primer sets as described earlier were used for
analysis of the expression of the gene for topoIIb (Tsai-Pflugfelder
et al. 1988),MDR1 (Noonan et al. 1990), and the glyceraldehyde-3-
phosphate dehydrogenase gene (Gekeler et al. 1994). Expression of
the topoIIa gene was determined using the Tyr-B05 region primer
set described above for SSCP analysis. PCR products were sepa-
rated on 1.75% agarose gels at 150 V for 2 h, stained with ethidium
bromide, visualized under UV illumination and photographed
using Polaroid 667 film. Products used for SSCP analysis (Danks
et al. 1993) were heated to 99°C in formamide for 6 min, placed on
ice allowing single DNA strands to retain their three-dimensional
conformation, and electrophoresed in a gel composed of 6%
acrylamide, 0.12% bisacrylamide, and 10% glycerol at 30 W for
9.5 h. Gels were put onto Whatman 3-mm paper, wrapped in
plastic and exposed to X-ray film (Kodak, Rochester, N.Y.).
Immunoblotting
For immunoblotting of topoIIa and topoIIb, whole-cell protein
lysates were prepared as described previously (Danks et al. 1988).
After being scraped from culture flasks, approximately 5 ´ 107 cells
were lysed in 1 ml buer (10 mM TRIS/HCl, 1 mM MgCl2,
0.1 mM CaCl2, pH 7.8) containing proteolysis inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1 mM benzamidine, 10 lg/ml soy-
bean trypsin inhibitor, 50 lg/ml leupeptin, 1 lg/ml pepstatin,
20 lg/ml aprotinin) on ice for 20 min. Cells were checked for lysis
by trypan blue and were then incubated for 20 min at 37°C after
addition of 120 units DNase I (Sigma). The protein amount was
quantified (BioRad protein assay) and 1 ll sample buer (0.125 M
TRIS/HCl, 20% glycerol, 4% SDS, 10% 2-mercaptoethanol,
0.004% bromophenol blue)/lg protein was added. Samples were
boiled for 2 min, and were loaded (50–100 lg protein) onto a 5%–
15% gradient sodium dodecyl sulfate/polyacrylamide gel and
electrophoresed for 3 h at 25 mA. Proteins were transferred to
nitrocellulose (Schleicher & Schu¨ll, Dassel, Germany) with a semi-
dry blot apparatus (Milliblot, Millipore, USA) at 2.5 mA/cm2 gel
for 55 min. Membranes were incubated overnight at 4°C with either
the anti-topoIIa polyclonal antibody MAC (Friche et al. 1992), or
anti-topoIIb polyclonal antibody (a kind gift of Dr. F. Boege,
University of Wu¨rzburg, Germany), diluted in blotting milk (0.9%
NaCl, 10 mM TRIS/HCl pH 7.5, 0.02% sodium azide, 5% dry
milk, 3% IgG-free bovine serum albumin, 0.2% Tween-20).
Membranes were then incubated with alkaline-phosphatase-linked
goat anti-(rabbit Ig) secondary antibody, and stained with 0.003%
5-bromo-4-chloro-3-indolyl phosphate and 0.006% nitrobluetet-
razolium chloride in TRIS buer (100 mM NaCl, 5 mM MgCl2,
100 mM TRIS, pH 9.5) until specific bands appeared. For detec-
tion of Pgp, cells were solubilized in 20 mM TRIS/HCl (pH 7.4),
containing 1 mM MgCl2, 2% v/v Triton X-100, 0.1% w/v SDS,
1% v/v dimethylsulfoxide and proteolysis inhibitors, overnight at
4°C. After centrifugation, the resulting supernatants were filtered
(0.45 lm filter) and immediately loaded onto a 7% acrylamide gel.
Resolved proteins were transferred to nitrocellulose, which was
incubated with the anti-Pgp monoclonal antibody C219. Further
incubations were successively performed with biotinylated goat
anti-(mouse IgG2a), streptavidin-biotinylated horseradish peroxi-
dase complex, and freshly prepared chemiluminescence Western
blotting detection reagent (Boehringer, Mannheim, Germany).
Finally, X-ray films were exposed to membranes for 0.2–1 min.
Methylation status of promoter DNA
Genomic DNA was isolated from approximately 2 ´ 107 cells, and
digested as previously described (Loflin et al. 1994). Restriction
enzymes StyI and XmnI (New England Biolabs, Beverly, Mass.)
were used to obtain the promoter region of the topoIIa gene
(Hochhauser et al. 1992). This 623-bp fragment was digested with
the restriction enzymes HhaI, HpaII and MspI (New England
Biolabs). All products were separated on 1.4% agarose gel, trans-
ferred to nylon membranes, and hybridized with a 32P-labelled
topoIIa-promoter probe (a generous gift of Dr. I.D. Hickson,
Oxford, England). X-ray films were exposed to membranes for
7 days.
Results
Expression of resistance and cross-resistance
in etoposide-selected RCC lines
Cells were exposed to chemoresistance-inducing regi-
mens until continuous growth was observed in the
presence of 10 lg etoposide/ml. Three sublines thus
obtained, RC2E derived from RC2, and RC21A and
RC21E, both derived from RC21, were used for further
studies. Expression of MDR phenotypes in these sub-
lines was tested by sensitivity assays with etoposide and
doxorubicin, both inhibitors of topoII, or vinblastine,
which does not inhibit topoII. Dose/response curves for
the parental and derived cell lines are shown in Fig. 1.
The results demonstrate that all the selected sublines
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have a reduced sensitivity to the topoII-inhibiting drugs,
as compared to the parental cell lines. The results of
several experiments are summarized in Table 1. Resis-
tance to etoposide was increased approximately 30-fold
for RC2E, 60-fold/RC21A and 90-fold for RC21E.
Enhanced resistance to doxorubicin (approximately 50-,
5-, 400-fold, respectively) was also observed for the same
set of cell lines. However, since etoposide and doxoru-
bicin are also known to be potential substrates for Pgp,
and RCC can express Pgp, the possible involvement of
Pgp was examined as well, by evaluation of the cross-
resistance to vinblastine. RC2E and RC21E were indeed
strongly cross-resistant to vinblastine (approximately
200- and 3500-fold increase respectively), whereas
RC21A appeared to be as sensitive as the parental RC21
cell line (Fig. 1, Table 1).
The stability of this resistance was checked monthly
for more than 1 year. MDR patterns of RC21E and
RC21A were stable during this period even without
monthly maintenance drug dosages of 1 lg/ml etoposide
for 2 days. RC2E lost its resistance 8 months after the
last concentration level of etoposide used (10 lg/ml).
Topoisomerase unknotting activity
The ATP-dependent strand-passing activity of topoII in
nuclear extracts of the cell lines was measured using P4
DNA as a substrate. P4 DNA was less eectively un-
Table 1 Cross-resistance and doubling times of RC2, RC21 and
sub-lines selected for resistance to etoposide. IC50 is the 50% in-
hibitory concentration in a growth-inhibition microtiter tetra-
zolium test. Values shown are means of three or more separate
experiments SD. Values were determined by graphical extra-
polation of growth curves. The doubling times were defined as the
number of hours required for cells in log-phase growth to double in
number and were determined graphically from growth curves
IC50 (lg/ml)
Drug RC2 RC2E RC21 RC21E RC21A
Vinblastine 0.03 6.53 0.004 14.9 0.002
0:01 6:39 0:002 6:19 0:001
Etoposide 1.68 54.4 0.79 70.2 45
0:87 44:7 0:22 9:03 17:4
Doxorubicin 0.21 9.59 0.05 19.6 0.31
0:08 7:53 0:01 5:59 0:22
Doubling time (h) 47 50 37 48 48
Fig. 1 Cytotoxicity of etoposide, doxorubicin and vinblastine as
determined by a microtiter tetrazolium test, measuring growth
inhibition, to RC2 (+), RC2E (n) (left panels), and RC21 (s),
RC21E (h) and RC21A (e) (right panels). Treatment with dierent
drug concentrations extended for twice the doubling-time of the cells.
Results are expressed as the mean  standard deviation of 8 wells of
a representative experiment
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knotted by extracts of line both cell lines with altered
topoIIa gene expression than by the parental cell line.
Figure 2 shows separate P4-DNA-unknotting assays of
the resistant lines compared to the parental cell line. The
amount of nuclear protein required for complete P4
DNA unknotting by the resistant cell lines RC21E and
RC21A was double that for RC21. The decreased ability
of comparable amounts of nuclear protein to unknot
P4 DNA indicates that resistance to etoposide of
RC21E and RC21A may be a consequence of altered
topoisomerase-associated MDR. Because we saw de-
creased topoII unknotting activity in the resistant sub-
lines RC21A and RC21E, but not in the resistant line
RC2E, we checked the expression of MDR1-related
genes.
RT-PCR studies
Expression of the resistance-associated genes was ex-
amined by RT-PCR, using specific primers. Results are
shown in Fig. 3. The level of expression of the ‘‘house-
keeping’’ gene for glyceraldehyde-3-phosphate dehy-
drogenase was used as a control for cDNA quantity.
The parental RC2 line and its resistant subline RC2E
had the same topoIIa mRNA expression (Fig. 3 upper
panel). In contrast, sublines RC21E and RC21A showed
a decreased level of topoIIa mRNA, compared to their
parental line. RC2E, which expressed resistance to vi-
nblastine, showed a slightly increased MDR1 mRNA
expression compared to RC2 (Fig. 3 lower panel). In
contrast to the vinblastine-sensitive lines RC21 and
RC21A, the resistant subline RC21E showed MDR1
expression. Expression signals of the topoIIb gene were
faint, but expression in RC2E and RC21A (Fig. 3 upper
panel) appeared to be slightly increased compared to
their parental lines.
Immunoblotting
The contents of Pgp, topoIIa and topoIIb were analyzed
by Western blotting of whole-cell protein extracted from
the parental cell lines and the derived sublines (Fig. 4).
Protein expressions were analyzed for at least three
Fig. 2 P4-DNA-unknotting assays comparing RC2E, RC21E and
RC21A activities with those of the parental cell lines RC2 or RC21
respectively. Indicated amounts of nuclear protein extracts (1.0 M
NaCl) were incubated with P4 DNA with and without ATP for
30 min. Full unknotting, a specific activity of topoisomerase II, is
reached when the band of knotted P4 DNA has disappeared. The
samples were treated with proteinase K and electrophoresed in a 0.7%
agarose gel. Results are representatives of three or more separate
experiments
Fig. 3 Analysis of drug-resistance-associated gene expression by
reverse transcriptase/polymerase chain reaction (RT-PCR) of RC2,
RC2E, RC21, RC21E and RC21A in two separate assays. Sample
products were visualised following 1% agarose gel electrophoresis.
The signal intensity of the glyceraldehyde-3-phosphate dehydrogenase
gene (GAPH) amplification products was used as a control for the
amount of RNA. Upper panel expression of topoisomerase (Topo)IIa
and topoIIb mRNA. Lower panel expression of MDR1 mRNA.
Results are representative of at least two separate experiments using
dierent RNA isolations
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dierent protein extractions of each cell line. The
amount of topoIIa protein in subline RC2E, which
demonstrated a high level of resistance against both
etoposide and vinblastine, was comparable to that in the
parental line RC2. Interestingly, both RC21A and
RC21E showed a substantial decrease in topoIIa protein
expression. The densitometrically determined amount of
protein showed a 3-fold reduction in the amount of
topoIIa in RC21A and RC21E, compared to RC21. The
overexpression of topoIIb protein in RC2E and RC21A
compared to the parental cell lines is in agreement with
the RT-PCR findings. While RC21 and RC21A had no
visible Pgp expression, sublines RC2E and RC21E, both
with decreased sensitivity to vinblastine, had increased
Pgp expressions. We can exclude involvement of MRP1
(Cole et al. 1992) in the MDR phenotype of our RCC
cell lines. MRP1 gene and protein expression was not
detectable by either immunocytochemistry (the antibody
was a kind gift of R. Scheper, Free University, Am-
sterdam, The Netherlands) or by RNase protection
assay (results, not shown, were obtained in collaboration
with K. Nooter, Erasmus University, Rotterdam, The
Netherlands).
SSCP analysis
To try to account for the decreased expression of
topoIIa protein, we examined by SSCP analysis two
regions of the topoIIa gene where, relatively infre-
quently, point mutations leading to functional aberra-
tions are known to occur (Danks et al. 1993), changing
the ATP-binding region (ATP-binding sites: motif B and
DNBS) and the DNA-binding region (adjacent to Tyr-
805). Mutations in the ATP- and DNA-binding regions,
as seen in the CEM/VM-1-5 cells, may result in changed
protein configuration and decreased enzymatic activity.
Results of the analysis of nucleotides 1323–1534, con-
taining the motif B and DNBS sites, are shown in Fig. 5.
No conformational dierences were found in the single-
stranded PCR products of all of the RCC lines, as they
migrated as those of the CEM cell line, which has no
mutations. Only the PCR product of CEM/VM-1-5
cDNA showed a third band, which is due to a mutation
in this region in one of its alleles. Also, no alterations
were found in the ATP-binding region of the parental
and resistant RCC cell lines (results not shown).
Methylation status
Since methylation of gene promoter sites can result in
gene inactivation (Cedar 1988), we examined the meth-
ylation status of the promoter region of the topoIIa gene
in RC21E and RC21 cells. RC21A was not analyzed
because this is a precursor of RC21E, unlikely to exhibit
changes that are not seen in the latter line. Restriction
enzyme analysis using HhaI and HpaII (cutting at
unmethylated sites only) and MspI (cutting at the same
sites as HpaII regardless of the methylation status) was
applied to identify possible resistance-related dierences
(Harker et al. 1995; Jones and Buckley 1990). Figure 6
shows that identical patterns were obtained for RC21
and RC21E topoIIa-gene-promoter DNA with HhaI
(94-bp and 529-bp fragments),HpaII (43-bp, 241-bp and
338-bp fragments) or with MspI (the same fragments as
with HpaII). We conclude that hypermethylation of the
promoter region of the topoIIa gene does not seem to
play an important role in the decreased transcription
level of topoIIa RNA.
Fig. 4 Immunoblot analysis of topoIIa, topoIIb and P-glycoprotein
(Pgp) from RC21, RC21A, RC21E, RC2 and RC2E cells. The
expressions in the cell lines demonstrated were obtained in one gel run
for each protein indicated. For analysis, cell fractions from each cell
line were subjected to SDS-PAGE and the separated proteins were
transferred to a nitrocellulose filter; the filters were then prepared as
indicated in Materials and methods
Fig. 5 Autoradiogram of a single-strand conformational polymor-
phism gel showing migration of PCR products of the motif B/DNBS
sequences of topoIIa cDNA generated from RNA of CEM, CEM/
VM-1-5, parental and resistant renal cell carcinoma (RCC) cells.
Mutated PCR products of CEM/VM-1-5, with a known mutation at
nucleotide 1346, migrated more slowly than those from CEM cells
(controls, without any mutations). The three bands shown by CEM/
VM-1-5 contain both normal and mutated alleles of the complemen-
tary single-stranded DNA fragments, but the upper band, containing
a normal and a mutant allele, is not separated by the electrophoresis




The nuclear enzymes topoI and topoII are the targets of
many known drugs that stabilize complexes of broken
DNA strands and protein (Pommier 1993). Most of
these drugs stabilize covalent complexes of topoII and
broken DNA strands that are formed during specific
phases of the cell cycle, leading to apoptotic cell death
(Walker et al. 1991) by mechanisms that are incom-
pletely understood. Alterations of the level of topoII
activity, which can be caused by a variety of mecha-
nisms such as topoIIa gene mutations (Danks et al.
1993; Hinds et al. 1991; Nitiss et al. 1993), post-trans-
lational modifications (Devore et al. 1992; Takano et al.
1991), or a reduced amount of the enzyme (Friche et al.
1991; Gudkov et al. 1993; Liu 1989), will therefore
modulate the eectiveness of topoII-specific drugs. If
fewer complexes are stabilized, cells will be less vulner-
able to cytotoxic drugs and may become resistant. To
date, the majority of chemoresistance studies in RCC
have focused on the expression of Pgp, the MDR1 gene
product, as a cause of resistance to a broad range of
antineoplastic drugs. Since there is a considerable vari-
ability of Pgp expression in RCC, the unrewarding re-
sults of chemotherapeutic treatment for RCC can not
exclusively be explained by Pgp-mediated resistance. In
the present study, we found that at-MDR resistance,
associated with a reduced expression of the topoIIa gene
and protein, may contribute to the MDR phenotype in
RCC.
Cloned drug-resistant sublines RC2E, RC21A and
RC21E were generated from the parental, non-chemo-
selected, human RCC cell lines RC2 and RC21 by
stepwise exposure of cell cultures to increasing concen-
trations of etoposide. We showed that RC2E overex-
pressed Pgp, that RC21A exhibited a decreased amount
of topoIIa, and that RC21E developed both forms of
resistance. As a consequence, improvement of the che-
motherapeutic treatment of RCC may require drugs that
are substrates for neither Pgp-mediated MDR nor non-
Pgp-mediated MDR, such as at-MDR. Our panel of cell
lines, therefore, oers a new tissue-culture model that
can be used to identify novel chemotherapeutic agents,
including topoIIa-interactive drugs, and to investigate
the mechanisms of at-MDR resistance in RCC. It may
be possible that other mechanisms, which not have been
investigated yet, such as glutathione content or the ac-
tivity of glutathione transferase, may be part of the
MDR phenotype as well. Involvement of multidrug-
resistance-associated protein 1 (MRP1), a cell-mem-
brane-bound protein, is excluded in these cell lines.
We observed a reduced growth rate and altered
growth pattern or cell cultures of RCC cells expressing
reduced amounts of topoIIa protein. In contrast to the
parental RC21 cell line, the sublines continue to prolif-
erate after reaching confluence, resulting in the forma-
tion of multilayer colonies. Reduced growth rate has
also been described for other cancer cell lines (Danks
et al. 1988), which may complicate the interpretation of
the growth-inhibiting eects of drugs. However, the re-
duced cytotoxic eects of topoII-inhibiting drugs will
likely lead to quantifiable tumor expansion. Another
consequence of the reduced growth rate can be that the
cloning procedure of the resistant sublines may not have
resulted in the selection of the most resistant cells. The
cloning technique, which selects colonies formed from a
single cell, will favor faster-growing cells. Thus, for re-
liable comparisons, growth-adjusted IC50 values should
be used for the determination of cytotoxicity.
Occasionally, an indirectly correlated expression of
the topoI and topoIIa genes is seen in cells resistant to
topoisomerase inhibitors, which might be interpreted as
a compensatory mechanism (Woessner et al. 1992).
Others found a direct correlation between topoIIa and
topoIIb gene expression (Brown et al. 1995; Kaufmann
et al. 1994). We observed increased topoIIb protein ex-
pression in RC21A cells and reduced topoIIa, which
would be in accordance with the idea of compensation.
It remains unclear why RC2E expresses an increased
amount of topoIIb protein, without reduced expression
of topoIIa. Thus, up-regulation of topoIIb protein
might be regarded as an optional mechanism of com-
pensation for a decrease in topoIIa protein. However,
topoIIb gene expression does not seem to aect cellular
P4-DNA-unknotting activity, since RC2E, with in-
creased topoIIb expression, showed unaected unknot-
ting activity, compared to the parental RC2. In addition,
RC21A showed decreased unknotting activity, although
it expresses increased topoIIb protein, compared to pa-
rental RC21.
Decreased amounts of topoIIa, seen in RC21A and
RC21E, are matched by decreased mRNA expression,
suggesting that these lines express the at-MDR pheno-
type. Also, we detected no point mutations in the regions
of the gene encoding the motif B/DNBS and Tyr-805, as
analyzed with SSCP. These regions represent areas in the
topoIIa gene sequences in which some point mutations
Fig. 6Methylation analysis of the DNA of the topoIIa gene promoter
(623 bp) from RC21 and RC21E cells. HhaI (digesting unmethylated
GCGC sites), HpaII (digesting unmethylated CCGG sites) and Msp1
(digesting the same CCGG sites, methylated and unmethylated)
produced identical fragments of 94 bp and 529 bp or 241 bp and
338 bp, respectively, from both RC21 and RC21E (94-bp fragment
not visible)
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were found in other malignancies (Danks et al. 1993).
The occurrence of mutations in other parts of the gene
cannot be excluded, however. On the other hand, test
conditions used to run the gels are claimed to be highly
ecient for the specified regions. Nevertheless, it appears
that reduced activity of topoII in the drug-resistant
sublines, as assessed by P4-DNA-unknotting activity, is
due to decreased expression of the topoIIa gene.
In our initial investigations for a possible cause of the
decreased topoIIa gene expression, we measured tran-
scription activity of the topoIIa gene, in part by com-
paring the methylation status of the promoter region of
the topoIIa gene in the RC21 and RC21E cell lines; we
found no dierences between these cell lines (Fig. 6),
and the topoIIa gene promoter was hypomethylated.
Methylation of RC21A was not investigated since
RC21E was established by continuous exposure of
RC21A to etoposide, when decrease of topoIIa gene
expression had already taken place. It is, therefore,
highly unlikely that changes in RC21A could be detected
that would not found in RC21E also. Our results suggest
that a decrease in topoIIa protein in RC21E cells is
likely due to other mechanisms of gene regulation. One
possible mechanism for such gene regulation is trans-
activation of the Sp1 and Sp3 proteins. These proteins
might activate or inhibit the promoter region of the
topoIIa gene respectively, as has been described in other
cell lines (Kubo et al. 1995).
RCC cells, which are almost always resistant to a
broad range of antineoplastic drugs, are well known to
express MDR1 and Pgp. The established RCC cell lines
overexpress MDR1 and are highly resistant to vinblas-
tine, but it has become clear that at-MDR likely con-
tributes to the drug-resistance profile in RCC. The
observed resistance to topoII inhibitors of at-MDR
RCC cell lines appears to be related to a decrease in
topoIIa gene and protein expression. Expression of the
topoIIa gene in clinical specimens, when primary cul-
tures are used, has already indicated a possible in-
volvement of at-MDR in RCC (Volm et al. 1993).
However, a direct relationship between expression and
resistance was not investigated in that study. The im-
mortal and cloned cell lines described in this paper
showed such a relationship in RCC cells. These lines,
with their defined resistance profiles and expression
patterns of resistance markers, oer a model suitable
for extensive in vitro investigation of drug development
in RCC, and for elucidating the mechanism of topoII
activity and regulation of gene expression. Future
studies with this model should yield information on the
drug-resistance profiles of new chemotherapeutic agents
and may contribute to improved treatment of clinical
RCC.
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